Plasma exchange for kidney disease: What is the best evidence?

Advances in Chronic Kidney Disease

Volumn 21, Issue 2, 2014, Pages 217-227

  Hildebrand, Ainslie M ^a,b   Huang, Shih Han S ^a,b   Clark, William F ^a,b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Kidney disease; Kidney transplantation; Plasma exchange; Thrombotic microangiopathy; Vasculitis

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ANCA ASSOCIATED VASCULITIS; ANTIGLOMERULAR BASEMENT MEMBRANE DISEASE; CRYOGLOBULINEMIA; FOCAL GLOMERULOSCLEROSIS; HUMAN; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MULTIPLE MYELOMA; PLASMAPHERESIS; PRIORITY JOURNAL; REGISTER; REVIEW; THERAPEUTIC PLASMA EXCHANGE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PLASMA EXCHANGE; THROMBOTIC MICROANGIOPATHY; VASCULITIS;

ALLOGRAFTS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CRYOGLOBULINEMIA; EVIDENCE-BASED MEDICINE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MULTIPLE MYELOMA; PLASMA EXCHANGE; RECURRENCE; THROMBOTIC MICROANGIOPATHIES;

EID: 84896883242     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.01.008     Document Type: Review

References (101)

1. Kaplan A.A., Halley S.E. Plasma exchange with a rotating filter. Kidney Int 1990, 38(1):160-166.
2. Lockwood C.M., Boulton-Jones J.M., Lowenthal R.M., Simpson I.J., Peters D.K. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. BMJ 1975, 2(5965):252-254.
3. Kaplan A.A. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008, 52(6):1180-1196.
4. Canadian Apheresis Group Data Reports. Paper presented at: Canadian Apheresis Group 2013 Annual General Meeting; April 12-14, 2013; Winnipeg, Manitoba, Canada.
5. Clark W.F., Rock G.A., Buskard N., et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999, 131(6):453-462.
6. Schwartz J., Winters J.L., Padmanabhan A., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013, 28(3):145-284.
7. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group KDIGO Clinical Practice Guideline for glomerulonephritis. Kidney Int Suppl 2012, 2:139-274.
8. George J.N. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010, 116(20):4060-4069.
9. Siegler R.L., Pavia A.T., Christofferson R.D., Milligan M.K. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994, 94(1):35-40.
10. Zheng X.L., Sadler J.E. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008, 3:249-277.
11. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987, 32(2):292-308.
12. Amorosi E.L., Ultmann J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966, 45(2):139.
13. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339(22):1585-1594.
14. Fujimura Y., Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 2010, 49(1):7-15.
15. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325(6):393-397.
16. Henon P. Presse Med 1991, 20(36):1761-1767.
17. Michael M., Elliott E.J., Ridley G.F., Hodson E.M., Craig J.C. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009, (1):CD003595.
18. Michael M., Elliott E.J., Craig J.C., Ridley G., Hodson E.M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009, 53(2):259-272.
19. Forzley B.R., Sontrop J.M., Macnab J.J., Chen S., Clark W.F. Treating TTP/HUS with plasma exchange: a single centre's 25-year experience. Br J Haematol 2008, 143(1):100-106.
20. Brunskill S.J., Tusold A., Benjamin S., Stanworth S.J., Murphy M.F. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2007, 17(1):17-35.
21. Clark W.F., Forzley B.R., Sontrop J.M., et al. TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trials. Kidney Int Suppl 2009, 112:S50-S51.
22. Nguyen L., Li X., Duvall D., Terrell D.R., Vesely S.K., George J.N. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 2008, 48(2):349-357.
23. George J.N., Charania R.S. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013, 39(2):153-160.
24. Clark W.F. Plasma exchange for renal disease: evidence and use 2011. J Clin Apher 2012, 27(3):112-116.
25. Garg A.X., Suri R.S., Barrowman N., et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003, 290(10):1360-1370.
26. Menne J., Nitschke M., Stingele R., et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012, 345:e4565.
27. Waters A.M., Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 2011, 26(1):41-57.
28. Ariceta G., Besbas N., Johnson S., et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009, 24(4):687-696.
29. Taylor C.M., Machin S., Wigmore S.J., Goodship T.H., working party from the Renal Association, the British Committee for Standards in Haematology, and the British Transplantation Society Clinical Practice Guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010, 148(1):37-47.
30. Licht C., Weyersberg A., Heinen S., et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005, 45(2):415-421.
31. Caprioli J., Noris M., Brioschi S., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108(4):1267-1279.
32. Legendre C.M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368(23):2169-2181.
33. Pusey C.D. Anti-glomerular basement membrane disease. Kidney Int 2003, 64(4):1535-1550.
34. Saus J., Wieslander J., Langeveld J.P., Quinones S., Hudson B.G. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 1988, 263(26):13374-13380.
35. Savage C.O., Pusey C.D., Bowman C., Rees A.J., Lockwood C.M. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. BMJ 1986, 292(6516):301-304.
36. Wilson C.B., Dixon F.J. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973, 3(2):74-89.
37. Johnson J.P., Moore J., Austin H.A., Balow J.E., Antonovych T.T., Wilson C.B. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985, 64(4):219-227.
38. Levy J.B., Turner A.N., Rees A.J., Pusey C.D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001, 134(11):1033-1042.
39. Kallenberg C.G., Brouwer E., Weening J.J., Tervaert J.W. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994, 46(1):1-15.
40. De Groot K., Harper L., Jayne D.R.W., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med 2009, 150(10):670-680.
41. Harper L., Morgan M.D., Walsh M., et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012, 71(6):955-960.
42. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
43. Jones R.B., Cohen Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363(3):211-220.
44. Glöckner W.M., Sieberth H.G., Wichmann H.E., et al. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. Clin Nephrol 1988, 29(1):1-8.
45. Pusey C.D., Rees A.J., Evans D.J., Peters D.K., Lockwood C.M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991, 40(4):757-763.
46. Cole E., Cattran D., Magil A., et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992, 20(3):261-269.
47. Jayne D.R.W., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18(7):2180-2188.
48. Rifle G., Chalopin J.M., Zech P., et al. Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study. Proc Eur Dial Transplant Assoc 1981, 18:493-502.
49. Mauri J.M., Gonzales M.T., Poveda R., et al. Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis. Plasma Ther Transfus Technol 1985, 6:587-591.
50. Guillevin L., Cevallos R., Durand-Gasselin B., Lhote F., Jarrousse B., Callard P. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris) 1997, 148(3):198-204.
51. Szpirt W., Rasmussen N., Petersen J. Long term outcome and prognostic factors in randomized study of plasma exchange and cyclosporine A in Wegeners granulomatosis. J Am Soc Nephrol 1999, 10(11):A1.
52. Walsh M., Catapano F., Szpirt W., et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011, 57:566-574.
53. Walsh M., Casian A., Flossmann O., et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013, 84(2):397-402.
54. Lionaki S., Falk R.J. Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis. J Am Soc Nephrol 2007, 18(7):1987-1989.
55. Walsh M., Merkel P.A., Peh C.A., et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013, 14:73.
56. Brouet J.-C., Clauvel J.-P., Danon F., Klein M., Seligmann M. Biologic and clinical significance of cryoglobulins. Am J Med 1974, 57(5):775-788.
57. Tarantino A., Campise M., Banfi G., et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995, 47(2):618-623.
58. Agnello V. Mixed cryoglobulinaemia after hepatitis C virus: more and less ambiguity. Ann Rheum Dis 1998, 57(12):701-702.
59. Dominguez J.H., Sha E. Apheresis in cryoglobulinemia complicating hepatitis C and in other renal diseases. Ther Apher 2002, 6(1):69-76.
60. Rockx M.A., Clark W.F. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci 2010, 42(3):247-251.
61. Pietrogrande M., De Vita S., Zignego A.L., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10(8):444-454.
62. Evans T.W., Nicholls A.J., Shortland J.R., Ward A.M., Brown C.B. Acute renal failure in essential mixed cryoglobulinemia: precipitation and reversal by plasma exchange. Clin Nephrol 1984, 21(5):287-293.
63. Briganti E.M., Russ G.R., McNeil J.J., Atkins R.C., Chadban S.J. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002, 347(2):103-109.
64. Sever S., Trachtman H., Wei C., Reiser J. Is there clinical value in measuring suPAR levels in FSGS?. Clin J Am Soc Nephrol 2013, 8(8):1273-1275.
65. Wei C., El Hindi S., Li J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17(8):952-960.
66. Bock M.E., Price H.E., Gallon L., Langman C.B. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 2013, 8(8):1304-1311.
67. Davenport R.D. Apheresis treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation: re-analysis of published case-reports and case-series. J Clin Apher 2001, 16(4):175-178.
68. Matalon A., Markowitz G.S., Joseph R.E., et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 2001, 56(4):271-278.
69. Deegens J.K.J., Andresdottir M.B., Croockewit S., Wetzels J.F.M. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 2004, 17(3):151-157.
70. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO Clinical Practice Guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9(suppl 3):S1-S157.
71. Wolfe R.A., Ashby V.B., Milford E.L., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341(23):1725-1730.
72. 2011 OPTN/SRTR Annual Report: transplant data 2001-2011. Available at. Accessed November18, 2013. http://www.ustransplant.org.
73. Stegall M.D., Gloor J., Winters J.L., Moore S.B., Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006, 6(2):346-351.
74. Montgomery R.A., Zachary A.A., Racusen L.C., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000, 70(6):887-895.
75. Schweitzer E.J., Wilson J.S., Fernandez-Vina M., et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000, 70(10):1531-1536.
76. Montgomery R.A., Lonze B.E., King K.E. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011, 365(4):318-326.
77. Warren D.S., Zachary A.A., Sonnenday C.J., et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004, 4(4):561-568.
78. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18(4):1046-1056.
79. Singh N., Pirsch J., Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev 2009, 23(1):34-46.
80. Böhmig G., Regele H. Diagnosis and treatment of antibody-mediated kidney allograft rejection. Transpl Int 2003, 16(11):773-787.
81. Ibernón M., Gil-Vernet S., Carrera M., et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc 2005, 37(9):3743-3745.
82. Min L., Shuming J., Zheng T., et al. Novel rescue therapy for C4d-positive acute humoral renal allograft rejection. Clin Transplant 2005, 19(1):51-55.
83. Faguer S., Kamar N., Guilbeaud-Frugier C., et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007, 83(9):1277-1280.
84. White N.B., Greenstein S.M., Cantafio A.W., et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004, 78(5):772-774.
85. Lefaucheur C., Nochy D., Andrade J., et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009, 9(5):1099-1107.
86. Brown C.M., Abraham K.A., O'Kelly P., Conlon P.J., Walshe J.J. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc 2009, 41(9):3690-3692.
87. Clark W.F., Stewart A.K., Rock G.A., et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005, 143(11):777-784.
88. Löw A., Hotze A., Krapf F., et al. The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis. Rheumatol Int 1985, 5:69-72.
89. Goto H., Matsuo H., Nakane S., et al. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher 2001, 5:494-496.
90. Lockwood C.M., Worlledge S., Nicholas A., Cotton C., Peters D.K. Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 1979, 300(10):524-530.
91. Ibrahim R.B., Liu C., Cronin S.M., et al. Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 2007, 27:1529-1549.
92. Ibrahim R.B., Balogun R.A. Medications and therapeutic apheresis procedures: are we doing our best?. J Clin Apher 2013, 28:73-77.
93. Ibrahim R.B., Balogun R.A. Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. Semin Dial 2013, 25:176-189.
94. Zäuner I., Bach D., Braun N., et al. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 2002, 39(1):28-35.
95. Stigelman W.H., Henry D.H., Talbert R.L., et al. Removal of prednisone and prednisolone by plasma exchange. Clin Pharm 1984, 3:402-407.
96. Samtleben W., Mistry-Burchardi N., Hartmann B., et al. Therapeutic plasma exchange in the intensive care setting. Ther Apher 2001, 5:351-357.
97. Darabi K., Berg A.H. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006, 125:592-597.
98. Yomtovian R., Niklinski W., Silver B., Sarode R., Tsai H.-M. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004, 124:787-795.
99. TM 2014, Lexi-Comp, Inc., Hudson, OH.
100. Bunn D., Lea C.K., Bevan D.J., Higgins R.M., Hendry B.M. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996, 45:29-32.
101. Soliris® (eculizumab) [package insert] 2011, Alexion Pharmaceuticals, Cheshire, CT.